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Background: Neuromyelitis optica spectrum disorder (NMOSD) is a clinically defined,
inflammatory central nervous system (CNS) disease of unknown cause, associated with
humoral autoimmune findings such as anti-aquaporin 4 (AQP4)-IgG. Recent clinical trials
showed a benefit of anti-B cell and anti-complement-antibodies in NMOSD, suggesting
relevance of anti-AQP4-IgG in disease pathogenesis.
Objective: AQP4-IgG in NMOSD is clearly defined, yet up to 40% of the patients
are negative for AQP4-IgG. This may indicate that AQP4-IgG is not disease-driving in
NMOSD or defines a distinct patient endotype.
Methods: We established a biobank of 63 clinically well-characterized NMOSD patients
with an extensive annotation of 351 symptoms, patient characteristics, laboratory results
and clinical scores. We used phylogenetic clustering, heatmaps, principal component
and longitudinal causal interference analyses to test for the relevance of anti-AQP4-IgG.
Results: Anti-AQP4-IgG was undetectable in 29 (46%) of the 63 NMOSD patients.
Within anti-AQP4-IgG-positive patients, anti-AQP4-IgG titers did not correlate with
clinical disease activity. Comparing anti-AQP4-IgG-positive vs. -negative patients did not
delineate any clinically defined subgroup. However, anti-AQP4-IgG positive patients had
a significantly (p = 0.022) higher rate of additional autoimmune diagnoses.
Conclusion: Our results challenge the assumption that anti-AQP4-IgG alone plays
a disease-driving role in NMOSD. Anti-AQP4-IgG might represent an epiphenomenon
associated with NMOSD, may represent one of several immune mechanisms that
collectively contribute to the pathogenesis of this disease or indeed, anti-AQP4-IgGmight
be the relevant factor in only a subgroup of patients.
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Key Messages:
• No clinical differences between anti-AQP4-IgG positive or
negative patients
• No significant change of anti-AQP4-IgG levels during disease
progression, but a non- significant increase in the mean anti-
AQP4-IgG titer was visible only after multiple relapses
• anti-AQP4-IgG+ patients have a significantly (p = 0.022)
higher rate of additional autoimmune diagnoses.
INTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD) is a rare
[prevalence about 1:100,000; incidence 0.1-0.4 per 100,000
(1–4)], devastating chronic inflammatory CNS disease. There
is no clear cause for the disease, and NMOSD in the
past had a grim prognosis in many cases due to limited
therapeutic options (1, 5–7). NMOSD is clinically characterized
by attacks of uni- or bilateral optic neuritis (ON), acute
myelitis and/or brain/brainstem encephalitis (8) and is associated
with specific autoantibodies (aAbs) such as anti-aquaporin-
4 (AQP4), targeting an astrocytic water channel (9), or
anti-myelin oligodendrocyte glycoprotein (MOG)-IgG (5, 10).
Approximately 60% of all NMOSD patients are positive for
anti-AQP4-IgG (11–13). Anti-AQP4-IgG is therefore thought
to play a key or even causal role in disease pathogenesis,
characterizing the anti-AQP4-IgG positive subset of NMOSD as
a channelopathy (11).
There are several other lines of evidence suggesting that
NMOSD is a humoral autoimmune disease: (1) Detection
of substantial local deposition of vasculocentric, activated
complement in active lesions in patients (14); (2) Recapitulation
of NMOSD-like clinical features in rodents following passive
transfer of patient serum (15, 16); (3) Capacity of NMO-
IgG to bind to the extracellular domain of AQP4 on
astrocytes and activate complement in vitro (17, 18); and
(4) Quantitative measures of complement-mediated injury to
AQP4-expressing cells in vitro could be correlated with clinical
disease progression in a limited number of patients (19).
Indeed, a recent clinical trial with eculizumab, a complement
factor 5 (C5) antibody, demonstrated clinical efficacy in
anti-AQP4-IgG-positive patients, supporting the notion that
NMOSD is a complement-dependent disorder of the CNS (20,
Abbreviations: ARR, annual relapse rate; AD, Alzheimer’s disease; aAgs,
autoantigens; AU, arbitrary unit; APC, antigen-presenting cell; AQP4, aquaporine-
4; ARR, annualized relapse rate; aAbs, autoantibodies; NMOSD, Neuromyelitis
optica spectrum disorder; BBB, blood-brain barrier; C5, complement factor
5; CNS, central nervous system; CXCL12, CXC motif ligand 12; dbGaP,
database of Genotypes and Phenotypes; EDSS, Expanded Disability Status
Scale; GI, gastrointestinal; GTEx, Genotype-Tissue Expression; HGNC, HUGO
gene nomenclature committee; HUGO, Human Genome Organization; IgG,
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resonance imaging;MSFC,Multiple Sclerosis Functional Composite; Nabs, natural
occurring antibodies; NGS, next generation sequencing; SF-36 score, 36-item
containing short form health survey; SVD, Singular Value Decomposition; ON,
optic neuritis; OCT, Optical coherence tomography; PCA, Principal component
analysis; PC, Principal components; SC, spinal cord.
21). Furthermore, complement-independent AQP4-antibody-
mediated astrocytopathies have been proposed from in vitro
cell culture models (22) and B cell targeting therapies such as
anti-CD20 and anti-CD19 have been shown to prevent relapses
and are now used as first line therapeutic options for this
disease (23–25).
Despite this evidence, more recent trials have failed to show
a correlation of complement-mediated cell killing activity with
relapse rates or relapse severity (26) and questioned the role
of anti-AQP4-IgG (27). In addition, in most rodent in vivo
models, neither induction of anti-AQP4-IgG by immunization,
its presence by transgenic anti-AQP4 expression nor continuous
infusion of anti-AQP4-IgG was sufficient to cause disease (16).
In these preclinical models, NMOSD-like pathology could only
be recapitulated if human (not murine) complement was co-
administered intracerebrally.
The question of the role and relevance of anti-AQP4-IgG is
of high therapeutic relevance, as only approximately between
half and two-thirds of the patients are positive for these
antibodies, and eculizumab has only been trialed in AQP4-
positive patients. Although NMOSD patients are clinically well-
defined and relatively homogeneous, and robust endotypes have
not been identified to date, the question of whether there exist
clinically relevant, AQP4-positive and AQP4-negative subtypes
has not been formally addressed.
Here, we investigated 63 clinically well-characterized NMOSD
patients to better understand the pathogenesis of this debilitating
disease and assess the relevance of anti-AQP4-IgG positivity.
Our results challenge the currently assumed, disease-driving
role for anti-AQP4-IgG, which holds therapeutic relevance
for NMOSD sufferers. Our findings also expand our present
understanding of antibody driven autoimmunity, complement
and neurodegeneration. However, we finally cannot prove nor
rule out that anti-AQP4-IgG might indeed play a major disease-
driving role in a subset of patients.
MATERIALS AND METHODS
NMOSD Patients
Demographic characteristics, diagnoses, medical history, age
at disease onset, time to diagnosis, duration of clinical
observation, clinical attacks, attack-related factors such as clinical
presentation, attack treatment, attack outcome and remission
rate, resulting disability, other therapies, short-term remission
status, laboratory values from routine tests, AQP4- and MOG-
aAb status as determined by cell-based assays [due to its
high relevance in this disease group (28–30)], annualized
relapse rate (ARR), optical coherence tomography (OCT)
(24) as well as magnetic resonance imaging (MRI) results
(31) and an array of other variables (Supplementary Table 1)
have been recorded from over 100 adult NMOSD patients
from an ongoing prospective longitudinal observational study
conducted at the NeuroCure Clinical Research Center of
Charité Universitaetsmedizin Berlin according to standardized
Wingerchuk 2015 criteria (32). In addition, an extensive test
battery including Expanded Disability Status Scale (EDSS),
Multiple Sclerosis Functional Composite (MSFC), The Short
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Form (36) Health Survey (SF-36), fatigue severity scale (FSS),
Fatigue Scale for Motor and Cognitive Functions (FSMC), Beck
Depression Inventory (BDI), McGill Pain Questionnaire (MPQ),
painDETECT questionnaire (PDQ), Brief Pain Inventory (BPI),
National Eye Institute Visual Function Questionnaire (NEI-
VFQ), National Eye Institute Visual Function Questionnaire
(NEI-VFQ), Neuro-Ophthalmic Supplement (NOS) and visual
analog scales (VAS) for general well-being, cognition, pain and
fatigue, were also included. A complete list of all 1,232 variables
can be found in Supplementary Table 1. We could include 351
of these variables in our analyses, all of which resulted in a
numeric, non-descriptive value or which could be turned into
a numeric result, and for which we had a reasonable amount of
tested subjects.
Inclusion criterion for patients was a diagnosis of NMOSD
according to Wingerchuk et al.’s 2015 criteria (32). The data
collection started in 2008 in order to merge and facilitate clinical
and research activities around NMOSD. Sixty-three patients had
full datasets and were included in further analyses, demographic
data and aAb status can be found in Supplementary Table 2.
These patients (79% female, mean age at diagnosis 45 years)
had a mean duration of disease of 4.1 years (median 5.5 years)
with a mean of 2.73 relapses (median two relapses) and a mean
disability of 7.42 points in the EDSS (median nine points)
after enrollment.
All data was stored, archived and disposed in a safe and secure
manner during and after the conclusion of the research project
in line with current data protection regulations (General Data
Protection Regulation: DSGVO). We have established policies
and procedures to manage data handled electronically as well
as through non-electronic means in accordance with good
laboratory practice.
Ethics Statement
All data collected from patients and investigated in this study was
used after written informed consent as approved by the ethics
committee of the Charité–Universitätsmedizin Berlin (proposal
EA1/041/14) according to the Declaration of Helsinki (59th
WMA General Assembly, Seoul, October 2008).
Statistical Analyses
Principal Component Analyses (PCA) and heatmap visualization
were performed using ‘ClustVis’ (33) as we did it before (34).
In brief, SVD (Singular Value Decomposition) with imputation
(as the most common method) or Nipals PCA model was
used to calculate the principal components (PC). PC 1 and 2
were presented on the X and Y axis while the percentages of
represented total variances were shown in brackets. Different
methods (Pareto, vector, or mostly Unit variance) were used
as scaling method applied to the rows or no scaling was used.
Imputation and SVD (or Nipals PCA) were iteratively performed
until estimates of missing values converged. We drew ellipses
for each dataset, datapoints fall with a probability of 0.95 inside
these ellipses.
In an attempt not to miss a fitting model due to artificial
fragmentation of patients’ populations due to overanalyses, we
used a stepwise approach based on our initially collected 1,232
variables. The most extensive set consisted of all 351 numeric
variables (listed in Supplementary Figure 1 on the Y-axis). We
also tested a medium sized set of 47 variables which was left after
the extensive clinical score details and deeply investigating single
symptom areas had been removed, leaving only the score results
in the dataset. Two further reduced sets of a limited number of
20 and 25 key variables were also analyzed, after variables dealing
with the relapses had been removed. This was done because we
had only data on relapses for a fraction of all patients. Finally,
a core set of 18 variables was analyzed after additional other
diagnoses (mainly further autoimmune diseases) of the patients
were removed.
Cladograms and heatmaps were generated after phylogenetic
cluster analyses were performed. Patients were clustered in
columns (shown on the X-axis) and variables were clustered in
rows (presented on the Y-axis) which were centered. Different
(correlation, binary, Canberra, Manhattan, maximum, euclidean
and most often correlation) distance and different (Ward as
unsquared distances, simple Ward, McQuitty, complete, single
and most often average) linkage methods were used as models,
as stated in the legends. Unit variance scaling was in some
analyses applied only to the variables in the rows. On top of
the rows, anti-AQP4 status or as an example the SF-36 variable:
“limitations due to pain” are shown in red and blue. Imputation
was used for missing value estimation. The results were expressed
as Z-scores.
Additional autoimmune diseases correlated with anti-AQP4-
IgG-positivity and we used chord plotting with “Circos” (35) to
demonstrate this.
Normal distribution was tested with the Anderson-
Darling, the D’Agostino & Pearson, the Shapiro-Wilk
and the Kolmogorov-Smirnov tests. An approximately
Gaussian distribution served as basis to perform Student’s
t and ANOVA tests using GraphPad Prism version 8.4.3
for Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com. Most data were not normally distributed,
we therefore used a non-parametric, unpaired and two-tailed
Mann–Whitney test. The null hypothesis of random results was
rejected if the P-value was very small <0.05.
Exon expression was used from GTEx (Genotype-Tissue
Expression) Analysis Release V8 (dbGaP, database of Genotypes
and Phenotypes, Accession phs000424.v8.p2) based on
expression data of AQP4: ENSG00000171885.13 from HGNC
(Human Genome Organization, HUGO Gene Nomenclature
Committee; HGNC Accession: 637; https://www.gtexportal.org/
home/gene/AQP4).
RESULTS
Anti-AQP4-IgG Status Does Not Define a
Subgroup
In order to better understand the spectrum of clinical and
pathological features of NMOSD, we established a biobank of
63 clinically well-characterized NMOSD patients regularly seen
at our institution (Supplementary Tables 1, 2) as part of an
ongoing observational study with an extensive annotation of 351
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singular symptoms, patient characteristics (such as biographic,
demographic, and social data), laboratory results, clinical scores,
imaging (MRI and OCT) findings and physical examination
results. Of these 63 patients, 34 were anti-AQP4-IgG+ and 29
were anti-AQP4-IgG−. anti-MOG-IgG could be identified in
18 patients, one patient was double positive for anti-AQP4-
IgG and anti-MOG-IgG. From this, we wanted to find a
mathematical model, which fits to the anti-AQP4-IgG-status
and correlates with the clinical variables. Therefore, we used
numerous mathematical models to test whether aAbs such as
anti-AQP4-IgG could play a role in the pathophysiology and the
clinical characteristics of NMOSD. We repeated those analyses
for different collections of variables as well as for the full set.
This was performed as it was not clear, how many and which
variables would be congruent and related to the anti-AQP4-IgG-
status. Specifically, we applied phylogenetic clustering, PCA and
longitudinal causal interference analysis.
We found that anti-AQP4-IgG status does not associate
with any subgroup of patients, characterized by patterns of
symptoms, patient characteristics, laboratory results, clinical
scores or findings (Figures 1, 2; Supplementary Figures 1–7),
as demonstrated by overlap of the 95% prediction ellipses in
PCA. Here all variables were converted to two most principal
components, to be able to plot it in 2D. There were no
anti-AQP4-IgG-dependent subgroups of patients identifiable,
irrespective of whether a PCA was performed with a basic set
of symptoms and clinical markers in the database (N = 20;
Figure 1A) or with the complete set (351 variables; Figure 1B;
Supplementary Figure 1). The anti-AQP4-IgG positive and
negative patients form again fully overlapping groups in all 57
cluster analyses performed for this study, independent of PCA
method, model used, as well as type or amount of input data.
Only two of the 57 models were exemplary, shown in Figure 1.
There was also a near full matching of the 0.95 CI prediction
ellipses of anti-AQP4-IgG positive and negative patients in the
PCAs. To show a contrary example, two distinct groups of
patients could be defined using the variables of the “36-item
containing short form health survey” (SF-36 score). The best
group-defining single value from those 36 variables was the
second pain variable (question 22) of this score, assessing the level
of interference of pain with normal work (including work outside
the home and housework) during the past 4 weeks. Figure 1C
shows a PCA based on the remaining 35 variables taken from
this score, except the mentioned pain variable two, for which the
patient cases have been colored. Patients having high (values 50,
75 and 100) vs. low levels (values 0 and 25) of this work disturbing
pain therefore form two different subgroups in the PCA (based
on the remaining 35 variables) with largely non-overlapping 0.95
CI prediction ellipses. This finding is independent of model and
data used.
We used the same datasets in Figure 2 for heatmap-based
phylogenetic clustering analyses. Again, a low number of 20
variables (Figure 2A) as well as a complete set of our database
(Figure 2B) leads to two major groups, which are independent
of anti-AQP4-IgG status (shown in red and blue on top of
the heatmaps). In Figure 2A the patient group in the left main
cluster are characterized by a higher age at disease onset, a higher
degree of unemployment and disability, lower levels of education,
higher scores in pain and fatigue questionnaires as compared
to the cluster on the right side. In contrast, the patients in the
right main cluster were younger at disease onset, report lower
pain levels, but score worse in functional scores such as EDSS
and MSFC.
In contrast, phylogenetic cluster analysis e.g., based only on
the variables from the SF-36 score as done for Figure 1C leads
to separation of two groups (Figure 2C): One mainly with high
levels of work disturbing pain (Figure 2 left side) and a group of
patients where all but one have low levels of the pain variable 2
(Figure 2 right side).
The anti-AQP4-IgG positive and negative patients form
almost always fully heterogeneous groups in all 57 cluster
analyses performed for this study, independent of clustering
method, model used, as well as type or amount of input data
(Figures 2A,B; Supplementary Figures 1–5).
Some subgroups roughly related only to a negative anti-
AQP4-IgG status could be found, but only with certain,
uncommon clustering methods (marked with green boxes in
Supplementary Figure 6) and if the number of variables were
extraordinarily reduced to 18. Specifically, only removal of all
information dealing with relapses, drugs, therapies and response
to therapy, all variables from more extensive clinical score
details (which investigated single symptom areas such as motor
function, vision, psychological scores, detailed characteristics
of pain etc.), all imaging data, as well as by removing all
data about additional other diagnoses led to formation of
these single subgroups with a negative anti-AQP4-IgG status.
Those remaining 18 variables consisted mainly of a set of
limited biographical data, while only the age at symptom onset
and diagnosis, the disability level and selected EDSS score
results were the remaining disease relevant markers. As the
more severely ill patients still always formed subgroups with
completely mixed anti-AQP4 status, this finding represents
very likely a stochastic artifact due to a high number of
clustering attempts.
Anti-AQP4-IgG-Titer Does Not Correlate
With Disease Activity
Anti-AQP4-IgG titers were determined as described previously
(36), but did not increase significantly with increased number
of attacks (Figures 3A,B) nor with increased disease activity,
measured as increased number of relapses per year (ARR;
Figure 3C). There was also no significant increase of the titer
with the number of affected symptom areas as a surrogate for
disease severity (Figure 3D). As higher disease activity (defined
as increased number of ARR) was not associated with an
increase of anti-AQP4-IgG titers, a biological gradient was not
apparent. Even if no significant change of anti-AQP4-IgG levels
could be identified after two relapses, a non-significant increase
in the mean anti-AQP4-IgG titer was visible with multiple
relapses. The mean titers (from 0.075 to 0.128), but not of
the median, increased after the third relapse as compared to
the second one. In addition, a non-significant increase in the
median could be noted between relapse one and two (from 0
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FIGURE 1 | Anti-aquaporin 4 (AQP4)-IgG status does not define distinct subgroups of patients by principle-component analyses (PCA) independent by model,
number or type of markers used. Anti-AQP4-IgG status does not define a subgroup (such as anti-AQP4-IgG positive and -negative patients) as demonstrated by the
full overlap of the 95% prediction ellipses in principle-component analyses (PCA). This is irrespective of how many and which markers are, or which model is used.
Patients with Neuromyelitis optica spectrum disorder (NMOSD) were colored according to their anti-AQP4-IgG-status (A,B) or the second pain variable, describing
levels of pain disturbing work during the last 4 weeks (question 22 from the “36-item containing short form health survey,” SF-36 score; in C). Singular value
decomposition (SVD) with imputation was used here in all PCAs to calculate principal components (PC). Prediction ellipses are such that with a probability of 0.95, a
new observation from the same group will fall inside the ellipse. (A) A PCA was performed with all variables (but not anti-AQP4 statuses) and the patients were marked
according to their anti-AQP4-IgG status. The PCA-plot shows PC1 and PC2, explaining 24 and 15% of the total variance, respectively, and was performed using only
a limited number of key variables (N = 20) such as the Expanded Disability Status Scale (EDSS), disease activity and severity, sex and age. Prediction ellipses were
drawn such that a new observation from the same group will fall inside the ellipse with a probability of 0.95. However, those prediction ellipses as well as the data
points completely overlap. No difference based on anti-AQP4-IgG status is visible. (B) As in A, but all 351 variables (symptoms, disabilities, lab values, anamnestic,
psychosomatic scores, and clinical markers) which have been recorded for the patients are included in the analysis, except for the anti-AQP4 statuses. Again, no
difference based on anti-AQP4-IgG status is visible, in marked contrast to (C): Same as in A but shown are patients having high vs. low levels of interference of pain
with normal work (including work outside the home and housework) during the past 4 weeks. A PCA based on the remaining 35 variables from the SF-36 score
(except the mentioned pain variable two, for which the patient cases have been colored) is shown. Here, the prediction ellipses for a probability of 0.95, as well as the
dots per se, show a remarkable difference between the two groups. AQP4, aquaporin 4; EDSS, Expanded Disability Status Scale; NMOSD, neuromyelitis optica
spectrum disorder; PC, principal components; PCA, principle-component analysis; SF-36, 36-item short form health survey; SVD, singular value decomposition.
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FIGURE 2 | The anti-aquaporin 4 (AQP4)-IgG status does not define a subgroup that would be detectable in heatmap-based clustering analyses. In addition to the
PCAs, the same data sets as in Figure 1 were used to perform calculations based on phylogenetic clustering analyses using heatmaps. As before, no difference
based on anti-AQP4-IgG status were identifiable. This is in contrast to the two clearly visible different groups, which are based on the second pain variable taken from
(Continued)
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FIGURE 2 | the 36-item short form health survey (SF-36). (A,B) Patients with Neuromyelitis optica spectrum disorder (NMOSD; N = 63) were clustered in columns
using correlation distance and average linkage based either on only a limited number of key variables, such disease activity, severity, sex and age etc. (A; N = 20) or
based on up to 351 symptoms and clinical markers (B; shown here in rows) were clustered. Unit variance scaling is applied to the symptoms and the clinical markers.
On top of the rows, anti-AQP4 status is shown. No group based on anti-AQP4-IgG status is visible. (C) As in (A,B), only the 35 variables of the SF-36 score were
used and the same patients were clustered. In contrast to anti-AQP4-IgG, on the left side of the dendrogram, clearly visible a major group based on a high pain
variable was formed. A difference to the anti-AQP4-IgG status can be seen due to the cluster on the left, formed by the residual variables of the SF-36 score. All
patients are positive for a high second pain variable. On top of the rows, the second pain variable taken from the SF-36 score is color encoded shown.
FIGURE 3 | Longitudinal causal interference analysis: anti-AQP4-IgG-Titer does not correlate with disease activity or progression. The level of anti-AQP4-IgG antibody
titers remain unchanged after increased number of attacks (A,B). Also, the number of relapses per year (ARR) do not correlate with the anti-AQP4-IgG status (C). The
level of anti-AQP4-IgG titers are not increased if more symptom areas are affected (D). A dichotomy can be seen if the level of anti-AQP4-IgG is plotted vs. the
anti-MOG-IgG titer (E): NMOSD patients which are anti-MOG-IgG positive do not have anti-AQP4-IgG and vice versa. AU, arbitrary unit.
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to 0.025), but no increase was found in the mean anti-AQP4-
IgG levels.
Mean titer of anti-AQP4-IgG after attack 1 was 0.134 (median
0; range 0–2.26; SD 0.362; 95% CI 0.026–0.241; N = 46), after
attack 2 it was 0.075 (median 0.025; range 0—.26; SD 0.099; 95%
CI 0.031–0.119; N = 22) and after attack 3 0.128 (median 0;
range 0–1.00; SD 0.2857; 95% CI −0.053–0.309; N = 12). There
was no increase in titer, if the first attack was compared with
the second (P = 0.365; 95% CI −0.239–0.575) or the second
with the third attack (P = 0.803; 95% CI −0.517–0.626). Also,
after two attacks there was no significant difference between
the titer from attack 1 and 3 (P = 0.606; 95% CI −0.676–
0.451; Figures 3A,B).
In addition, the ARR did not differ significantly (P = 0.351;
95% CI −0.206–0.571) between anti-AQP4-IgG positive (Mean
0.590; Median 0.414; range 0–4.000; SD 0.764; N = 34) and
negative (Mean 0.773; Median 0.667; range 0–3.000; SD 0.774;
N = 29) patients (Figure 3C).
The number of symptom areas affected (mean 0.563; median
0.500; range 0–3.000; SD 0.653; 95% CI 0.417–0.708; N = 80)
did not correlate (Pearson r = −0.050; P = 0.657) with the
titer of anti-AQP4-IgG (mean 0.117; median 0.000; range 0–
2.260; SD 0.299; 95% CI 0.050–0.183; N = 80; Figure 3D). The
number of attacks (mean 1.575; median 1.000; range 1–3; SD
0.743; 95% CI 1.410–1.740; N = 80) did also not correlate
(Pearson r = −0.036; P = 0.750) with the titer of anti-AQP4-
IgG (not shown).
NMOSD patients were either anti-MOG-IgG or anti-AQP4-
IgG single positive, or double negative (Figure 3E).
The titer of anti-AQP4-IgG (mean 0.121; median 0.000; range
0–2.260; SD 0.204; 95% CI 0.052–0.190;N = 77) did not correlate
(Pearson r = −0.066; 95% CI −0.286–0.160; P = 0.568) with
the titer of anti-MOG-IgG (mean 0.014; median 0.000; range
0–0.740; SD 0.086; 95% CI−0.005–0.033; N = 77; Figure 3E).
In addition to the cluster analyses and PCAs, we could not
identify any difference related to anti-AQP4-IgG inmore classical
analyses of various markers of disease history and severity,
including age at relapses, treatment plans, pain, visual function,
fatigue and psychometric scores (Supplementary Figure 7).
There was no significant difference in the temporal
characteristics of the history of disease (disease onset, diagnosis,
start and stop of therapies, ages at the first visit in our clinic as
well as ages at the relapses) for Anti-AQP4-IgG positive and
negative patients.
In full detail, in the “mean age at symptom onset (years)” with
a P of 0.54 (mean age 41.82 vs. 39.37 years (yrs); median 42.50
vs. 39.00 a; range 14–65 vs. 7–70; SD 14.68 vs. 16.37; 95% CI
36.70–46.95 vs. 32.89–45.85; N = 34 vs. 27), in the “mean age
at first diagnosis (years)” with a P of 0.84 (mean age 43.42 vs.
44.22 yrs; median 43.00 vs. 44.00 a; range 15–67 vs. 17–79; SD
14.26 vs. 15.51; 95% CI 38.37–48.48 vs. 38.09–50.36; N =3 3 vs.
27), in the “mean age at start of current therapy (years)” with a
P of 0.72 (mean age 45.32 vs. 43.82 ysr; median 45.00 vs. 47.00 a;
range 15–68 vs. 20–72; SD 14.23 vs. 15.05; 95% CI 39.80–50.84
vs. 37.15–50.49; N = 28 vs. 21), in the “mean age at start of
first therapy (years)” with a P of 0.98 (mean age 44.15 vs. 44.00
yrs; median 41.50 vs. 45.00 a; range 20–67 vs. 19–70; SD 13.33
vs. 15.30; 95% CI 37.91–50.39 vs. 35.17–52.83; N = 20 vs. 14),
in the “mean age at stop of current therapy (years)” with a P
of 0.85 (mean age 46.10 vs. 45.21 yrs; median 44.00 vs. 46.00 a;
range 28–68 vs. 20–71; SD 11.63 vs. 15.14; 95% CI 40.65–51.55
vs. 36.47–53.95;N =2 0 vs. 14), in the “mean age at first visit date
(years)” with a P of 0.54 (mean age 49.04 vs. 46.50 yrs; median
50.00 vs. 48.50 a; range 21–73 vs. 21–79; SD 14.28 vs. 15.43; 95%
CI 43.39–54.68 vs. 40.27–52.73; N = 27 vs. 26), in the “mean age
at relapse 1 (years)” with a P of 0.79 (mean age 41.58 vs. 40.44
yrs; median 42.50 vs. 39.00 a; range 14–66 vs. 7–70; SD 14.31 vs.
15.98; 95% CI 35.80–47.36 vs. 33.85–47.03; N = 26 vs. 25), in the
“mean age at relapse 2 (years)” with a P of 0.67 (mean age 44.38
vs. 42.25 yrs; median 46.00 vs. 44.00 a; range 14–66 vs. 9–70; SD
15.07 vs. 16.94; 95% CI 37.52–51.24 vs. 34.32–50.18; N = 21 vs.
20) or in the “mean age at relapse 3 (years)” with a P of 0.36 (mean
age 43.25 vs. 37.33 yrs; median 43.50 vs. 40.50 a; range 15–66 vs.
10–67; SD 15.86 vs. 17.23; 95% CI 34.80–51.70 vs. 26.38–48.28;N
= 16 vs. 12) as shown in Supplementary Figure 7A.
There was also no significant difference for Anti-AQP4-IgG
positive and negative patients regarding different treatments.
Anti-AQP4-IgG positive and negative patients did not differ
significantly in receiving Rituximab (mean 0.56 vs. 0.38 cycles;
median 1.00 vs. 0; range 0-1 for both; SD 0.50 vs. 0.49; 95%
CI 0.38–0.73 vs. 0.19–0.57; N = 34 vs. 29) with a P of 0.16,
Azathioprine (mean 0.15 vs. 0.14 cycles; median 0 for both; range
0-1 for both; SD 0.36 vs. 0.35; 95% CI 0.02–0.27 vs. 0.00–0.27;
N = 34 vs. 29) with a P of 0.92 or Mycophenolate mofetil (mean
0.03 vs. 0.07 cycles; median 0 for both; range 0-1 for both; SD 0.17
vs. 0.26; 95% CI −0.03–0.09 vs. −0.03–0.17; N = 34 vs. 29) with
a P of 0.47 (Supplementary Figure 7B).
We could also not identify any significant difference in pain
as well as in visual function scores. Anti-AQP4-IgG positive and
negative patients demonstrated no difference in the “McGill Pain
Questionnaire (MPQ)” (mean 30.50 vs. 28.69; median 36 vs. 29;
range 6–55 vs. 5–50; SD 14.38 vs. 15.61; 95% CI 22.84–38.16
vs. 19.26-38.12; N = 16 vs. 13) with a P of 0.75 (passed Test
for normal distribution), in the “painDETECT questionnaire
(PDQ)” (mean 28.10 vs. 26.15; median 28 vs. 20; range 2–49 vs.
9–63; SD 14.99 vs. 15.93; 95% CI 21.27–34.92 vs. 18.70–33.60; N
= 21 vs. 20) with a P of 0.69 (passed Test for normal distribution),
in the “Brief Pain Inventory (BPI)” (mean 34.50 vs. 35.64; median
35.5 vs. 28; range 10–54 vs. 2–78; SD 15.71 vs. 27.09; 95% CI
21.36–47.64 vs. 17.44–53.83;N= 8 vs. 11) with a P of 0.92 (passed
Test for normal distribution), in the “visual analog scale (VAS)
pain” (mean 35.43 vs. 31.88; median 34.0 vs. 26.5; range 0–100
vs. 0–98; SD 29.78 vs. 28.35; 95% CI 22.56–48.31 vs. 19.90–43.85;
N = 23 vs. 24) with a P of 0.54 (not normal distributed), in
the “National Eye Institute Visual Function Questionnaire (NEI-
VFQ)” (mean 107.6 vs. 113.5; median 109.0 vs. 113.0; range 58–
124 vs. 104–129; SD 12.88 vs. 7.20; 95% CI 102.0–113.1 vs. 110.5–
116.5; N = 23 vs. 25) with a P of 0.10 (not normal distributed)
or in the composite “National Eye Institute Visual Function
Questionnaire (NEI-VFQ) and Neuro-Ophthalmic Supplement
(NOS)” (mean 47.00 vs. 45.04; median 49 vs. 46; range 25–54
vs. 29–56; SD 6.82 vs. 6.03; 95% CI 44.05–49.95 vs. 42.55–47.53;
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N= 23 vs. 25) with a P of 0.30 (normal distributed) as shown in
Supplementary Figure 7C.
We also compared disability status Scales and could not
identify a difference. Anti-AQP4-IgG positive and negative
patients demonstrated no significant difference in the “Multiple
Sclerosis Functional Composite (MSFC)” with a P of 0.68 (mean
7.96 vs. 8.21; median nine for both; range 4–9 for both; SD 2.07
vs. 1.87; 95% CI 7.08–8.83 vs. 7.31–9.11; N= 24 vs. 19) as shown
in Supplementary Figure 7D.
There was no significant difference for Anti-AQP4-IgG
positive and negative patients in the “The Short Form (36) Health
Survey (SF-36)” with a P (passed Test for normal distribution)
of 0.56 (mean 97.78 vs. 99.04; median 99 vs. 101; range 80–
112 vs. 81–108; SD 7.99 vs. 7.01; 95% CI 94.33–101.2 vs. 96.15–
101.9; N = 23 vs. 25), in the “visual analog scale (VAS). general”
with a P (normal distributed) of 0.35 (mean 39.39 vs. 46.38;
median 35 vs. 57.5; range 0–100 vs. 0–82; SD 27.06 vs. 23.91;
95% CI 27.69–51.09 vs. 36.28–56.47; N = 23 vs. 24), in the
“visual analog scale (VAS) cognition” with a P (passed Test
for normal distribution) of 0.65 (mean 31.61 vs. 31.70; median
25 vs. 26; range 0–98 vs. 0–69; SD 30.11 vs. 24.40; 95% CI
18.59–44.63 vs. 21.15–42.25; N = 23 for both), in the “fatigue
severity scale (FSS)” with a P (data was normal distributed)
of 0.89 (mean 34.65 vs. 35.36; median 30 vs. 33; range 9–63
vs. 10–63; SD 18.70 vs. 15.19; 95% CI 26.57–42.74 vs. 29.09–
41.63; N = 23 vs. 25), in the “Fatigue Scale for Motor and
Cognitive Functions (FSMC)” with a P (passed Test for normal
distribution) of 0.96 (mean 36.90 vs. 36.58; median 29 vs. 38.5;
range 4–76 vs. 1–69; SD 21.24 vs. 19.75; 95% CI 27.23–46.57 vs.
28.25–44.92; N = 21 vs. 24), in the “Beck Depression Inventory
(BDI)” with a P (normal distributed data) of 0.30 (mean 9.32
vs. 11.82; median 7.5 vs. 10; range 1–27 for both; SD 7.42 vs.
8.36; 95% CI 6.03–12.61 vs. 8.11–15.52; N = 22 for both) or in
the “visual analog scale (VAS) fatigue" with a P (results fitted
to a normal distribution) of 0.22 (mean 36.61 vs. 46.67; median
23 vs. 54.5; range 0–100 vs. 0–76; SD 29.15 vs. 26.16; 95%
CI 24.00–49.22 vs. 35.62–57.71; N = 23 vs. 24) as shown in
Supplementary Figure 7E.
Even if a reduction of the Anti-AQP4-IgG titers was visible,
there was no statistically significant difference (P = 0.85; no
normal distribution) in the titer of Anti-AQP4-IgG between
rituximab treated patients and untreated patients (mean 0.09 vs.
0.19; median 0 for both; range 0–0.74 vs. 0–2.26; SD 0.17 vs. 0.51;
95% CI 0.02–0.16 vs.−0.04–0.42; N = 25 vs. 21) as shown in
Supplementary Figure 7F.
However, we identified a close to significant (P=0.09)
increased rate of malignomas in the anti-AQP4-IgG negative as
compared to the positive group (mean 0 vs. 0.10 malignomas;
median was 0 in both cases; range 0 vs. 0–1; SD 0 vs. 0.31; 95% CI
0–0 vs.−0.014–0.221;N= 34 vs. 29; not shown). Further analysis
showed that this increased rate in the anti-AQP4-IgG negative
group was not present in anti-MOG-IgG positive patients, but
only in anti-MOG-IgG negative patients (mean 0 vs. 0.20 tumors;
median was 0 in both; range 0 vs. 0–1; SD 0 vs. 0.42; 95% CI 0-
0 vs.−0.102–0.502; N = 17 vs. 10). However, this was even less
significant (P = 0.13; not shown).
Positive Anti-aquaporin 4 (AQP4)-IgG
Status Is Associated With Other
Autoimmune Diseases in Addition to
NMOSD
We identified a high number of additional diagnoses in addition
to NMOSD in our patient collective (Figure 4A). While double
aAb, anti-AQP4- and anti-MOG-IgG-negative patients had a
higher rate of malignancies, anti-AQP4-IgG+ patients had a
significantly (P = 0.022; Mann–Whitney test as not normal
distributed) higher rate of additional autoimmune diagnoses as
compared to anti-AQP4-IgG-negative patients (mean 0.47 in
AQP4-IgG+ vs. 0.07 in AQP4-IgG−; median was 0 in both;
range 0–4 vs. 0–1; SD 0.90 vs. 0.26; 95% CI 0.16–0.78 vs.−0.03–
0.17; N = 34 vs. 29; Figure 4B). Ten of the 34 anti-AQP4-IgG+
patients (29%) had at least one additional autoimmune disorder
as compared to only two of the 29 anti-AQP4-IgG− patients
(7%). Of those ten anti-AQP4-IgG+ patients, three had two and
one had even four additional autoimmune diseases.
The two leading additional autoimmune disease
were autoimmune thyroiditis in 4 and systemic lupus
erythematosus (SLE) in five of the anti-AQP4-IgG+ patients
(Supplementary Table 2). In contrast, none of the anti-
AQP4-IgG− patients had SLE and only one patient had
autoimmune thyroiditis.
DISCUSSION
In this study, anti-AQP4-IgG positive or negative subgroups
are not clearly associated with clinical parameters. The
observation that patients without anti-AQP4-IgG are not
clinically distinguishable from those patients with detected anti-
AQP4-IgG argues challenges the hypothesis that anti-AQP4-IgG
plays a major disease-driving role. However, we cannot exclude
that the autoantibody assays were made at the wrong time point
over the course of the disease. We used the data at baseline, the
first visit of the patient as it might change after relapse therapy
e.g., with rituximab.
This indiscernibility might be explained by either of the
following: (1) with anti-AQP4-IgG we detect a polyreactive aAb
and we know only one, maybe a minor, low affinity target of
this aAb; (2) Anti-AQP4-IgG is a secondary, disease sustaining
aAb (like in rheumatic fever), but not initiating it; patients can
still benefit clinically from targeting it; (3) Anti-AQP4-IgG is an
indicator for a yet unknown disease subgroup; or (4) Anti-AQP4-
IgG is an epiphenomenon without salient clinical relevance for
the course of NMOSD.
Emerging research suggests that autoimmune diseases, even
when mediated by T cells, will frequently accompany the
emergence of aAb to the same, often intracellular autoantigens
(aAgs) (37, 38). aAbs, whose serum levels correlate with disease
severity, have the potential to be used not only as biomarkers
but also to identify relevant T cell targets (39–41). Nevertheless,
the diversity and polyreactivity of aAbs in individuals with an
autoimmune condition poses a significant barrier to determining
which aAgs are pathogenic.
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FIGURE 4 | A positive anti-aquaporin 4 (AQP4)-IgG status is associated with the presence of other autoimmune diseases in addition to NMOSD, while a negative
status is associated with malignancies. A chord plot, based on the 59 patients for which we had both, anti-AQP4- and anti-MOG-IgG test results, is shown (A). The
patients were sorted according to these results into four groups, shown on the left side of the chord plot: anti-AQP4-IgG+ and anti-MOG-IgG+: double
AQP4+MOG-IgG positive anti-AQP4-IgG− and anti-MOG-IgG+: single MOG-IgG positive anti-AQP4-IgG+ and anti-MOG-IgG−: single AQP4-IgG positive
anti-AQP4-IgG− and anti-MOG-IgG−: no aAb. On the right side, key findings such as: number of relapses; any other autoimmune disease (thyroiditis; SLE;
myasthenia; Sjogren’s and other); diabetes; hypertension; any malignancy and traumatic injury are show. The thickness of the connecting chords between the four
patient subgroups and the key findings represents the number of patients with each of those conditions. The chords connecting the patients with “any malignancy”
have been colored red, however there is only one chord present, connecting “any malignancy” with the “anti-AQP4-IgG− and anti-MOG-IgG−: no aAb” group.
Therefore, all patients with malignancy do not have any of the aAbs. In contrast, the chords connecting patients with “any other autoimmune disease” have been
colored blue. The thickest chord, representing about 80% of the autoimmune group, is connected to the “single AQP4-IgG positive” patients. Vice versa, in this “single
AQP4-IgG positive” group, the connection to the autoimmune group represents about 40% of all its connections. Therefore, 80% of all patients with a second
autoimmune condition were single AQP4-IgG positive and in this group, it was the largest contributing factor and showed a significant difference related to the
AQP4-IgG status (B).
According to the Bradford Hill criteria, a biological gradient
should be present, to prove the causal role of a presumed
cause and an observed effect (disease) (42). This missing
biological gradient, the missing increase of the anti-AQP4-IgG
with increasing disease activity, is hard to explain. In other
autoimmune disease such as Lupus nephritis, there is a clear
correlation of severity of the clinical disease with anti-dsDNA-
autoantibodies (43, 44).
“Bystander” B cell responses have been observed in several
autoimmune diseases, Hashimoto’s thyroiditis being a good
example. In Hashimoto’s, high amounts of anti-thyroid aAb
are produced and correlate well with the clinical course (45).
These aAb can even fix complement and facilitate the destruction
of thyroid cells (46, 47). However, they are a consequence of
the disease process, not a cause (48, 49). Another example is
polymyositis, where anti-myoglobin aAbs correlate well with
clinical activity, but do not participate in the induction of
tissue destruction (50). Whether aAbs play a pathogenic role
in MS, a comparable CNS disease, remains unclear; but even
when they lack a causative role in disease, aAbs nevertheless
inform us about the identity of the aAgs that are available
and recognized by the autoimmune T cell population. Many
aAb are IgG type natural occurring antibodies (NAbs), which
are present from birth and not induced later (51, 52). NAbs
do not appear to depend on CD4T cell help, noteworthy
because anti-CD4 is ineffective in MS (53, 54). Identifying the
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targets of NAbs is technically challenging. NAbs purified with
immunoadsorbent columns with one aAg are often cross-reactive
to other aAgs (51). Polyreactivity is a big problem, as we need
to identify the set of best binding aAgs for each monoclonal
Ab, select the disease-relevant targets and define possible
pathogenic T cell epitopes of those aAgs (55). Nevertheless,
we have extensive experience in aAb characterization and have
developed protocols that overcome many of these challenges
(56, 57).
The initiation of disease, how the blood-brain barrier (BBB)
breaks down, is left unexplained. AQP4, the six transmembrane
helix water channel, is not expressed on endothelial cells,
therefore translocation of anti-AQP4-IgG through the BBB, due
to a leaky BBB and/or local production of it is required (58).
Those aAbs are thought to be of high pathophysiologic if not
etiologic relevance even as a myriad of other aAgs have now been
found in several major neurological diseases (37). As NMOSD
is thought to be caused by an autoimmune reaction and as
patients with NMOSD experience almost exclusively symptoms
due to CNS involvement, an expression of the target of this
autoimmune reaction limited selectively to the CNS would
fortify the pathological hypothesis. Many new isoforms of AQP4
just have been identified (Supplementary Figure 8) with broad
expression of the main transcript outside the CNS. Expression
data of AQP4: ENSG00000171885.13 from HGNC (Acc: HGNC:
637) shows eight splice variants (Supplementary Figure 8),
which represent different protein isoforms, the major one is
also highly expressed in the lungs, thyroid, gastrointestinal (GI)
system and other organs. Proteomics data reveals an AQP4
protein presence in lung and stomach which is comparable
to its presence in astrocytes. However, in patients with anti-
AQP4-IgG, pulmonary and gastric symptoms have not been
described. Yet there are studies investigating binding of
patients’ anti-AQP4-IgG against two of the major AQP4 forms
expressed on astrocytes (59), although others have proposed
that anti-AQP4-IgG may not be the main direct cause of
the astrocytopathy in NMOSD, but demonstrated that anti-
AQP4-IgG down-regulates CXC motif ligand 12 (CXCL12) and
impairs remyelination by oligodendrocyte progenitor cells (60).
Indeed, the high degree of heterogeneity of the patients’ IgGs
to targeting different isoforms of AQP4 raises the question
how well other isoforms are targeted, especially in non-
CNS organs.
However, there are four CNS-specific transcripts, of which
transcript six might be functional and exclusively use exon two,
making it an ideal target for a CNS-selective aAb leading to a
localized autoimmune reaction in NMOSD. In further studies,
we should also test those isoforms, splice variants as well as other
genotypes of AQP4 as target of the aAb. We cannot exclude that
anti-AQP4-IgG plays a prominent role at an earlier or later stage,
especially as the expression is heavily modified by inflammation
(especially IFNγ) (61).
AQP4 represents only one of many so far described IgG
aAgs in NMOSD such as anti-nuclear and anti-Ro aAbs (1, 62).
Thus, it is possible that several autoreactive IgG against several
targets collectively contribute to disease. The recent positive trial
data demonstrating efficacy of anti-CD19 in NMOSD indirectly
supports this notion (23, 63), although it should be noted that
B cells serve additional functions beyond merely manufacturing
IgG (64). Interestingly, we found no difference in anti-AQP4
status after treatment with rituximab, to which most patients
responded with a clinical improvement. Similar as what has been
described in other autoimmune diseases, a reduction in anti-
AQP4 status would have been conceivable (65). This might be
a further hint that the role of anti-AQP4-IgG as disease driving
aAb has been overestimated.
The finding that a positive anti-AQP4-IgG status is
significantly associated with the presence of other autoimmune
diseases in addition to NMOSD might indicate that anti-AQP4
is indeed a “bystander” B cell response as explained above.
Therefore, in some patients detectable anti-AQP4-IgG titers
may signify the co-occurrence of NMOSD and additional
autoimmune disease. In our patient cohort, five patients suffered
from additional SLE, four from autoimmune thyroiditis and
two from Sjogren’s syndrome. This pattern fits in with the
long-known association of NMOSD with these autoimmune
syndromes, which first led to the discovery of NMO-IgG and
turned out to be anti-AQP4-IgG (1). Interestingly, pathological
changes in the IgG half-life have been described in all of these
diseases, so that certain aAbs can be present at elevated titers
(66–69). In addition, B cell survival and activation is enhanced
in those autoimmune diseases (70). This might give a hint that
anti-AQP4-IgG might be present in other NMOSD patients,
but below the detection limits of the test as additional immune
pathologies are needed to make it detectable with the current
clinically used test procedures and available immunoassays. So
far, our results challenge the assumption that anti-AQP4-IgG
alone plays a disease-driving role in NMOSD as it is determined
with the currently used immunoassays. We cannot finally rule
out that Anti-AQP4-IgG might be the main pathologic factor
in a subset of patients, but our analyses rather indicate that it is
represent as an epiphenomenon or may be one of many immune
mechanisms that collectively contribute to the pathogenesis of
this disease.
In further studies, we would suggest evaluating the tissue
specific expression of the target, it’s splice variants, as well as a
possible polyreactivity of Anti-AQP4-IgG.Wewould also suggest
to use ex vivo translated AQP4 or more selective certain peptide
epitopes to improve the capability of the immunoassay.
CAPSULE SUMMARY
We performed phylogenetic clustering, PCA and causal
interference analyses to test for a role of anti-AQP4-IgG in
63 comparable patients suffering from NMOSD. Our results
challenge the current concept that anti-AQP4-IgG plays a sole
or predominant disease-driving role in many patients with
this disease.
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